49 results on '"Dhiver, Catherine"'
Search Results
2. RETRACTED ARTICLE: Dramatic HIV DNA degradation associated with spontaneous HIV suppression and disease-free outcome in a young seropositive woman following her infection
3. Publisher Correction: Dramatic HIV DNA degradation associated with spontaneous HIV suppression and disease-free outcome in a young seropositive woman following her infection
4. Pericarditis related to post-acute COVID infection: A case report and review of the literature
5. Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine
6. Genomic description and prevalence of two new Candidatus Saccharibacteria species from the human gut in different samples and countries
7. Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses
8. Dolutegravir and weight gain: an unexpected bothering side effect?
9. Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe
10. High penetration of doravirine in the central nervous system: What are the benefits?
11. Full-length title: Dramatic HIV DNA degradation associated with spontaneous HIV suppression and disease-free outcome in a young seropositive woman following her infection
12. Recombinant hepatitis C viruses that might hamper accurate genotype classification and choice of treatment with direct-acting agents, southeastern France
13. WITHDRAWN: Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients
14. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France
15. Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients
16. Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor
17. Hepatitis E virus infection in patients infected with the human immunodeficiency virus
18. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
19. Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV‐infected patients
20. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
21. Dramatic HIV DNA degradation associated with spontaneous HIV suppression and disease-free outcome in a young seropositive woman following her infection
22. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy
23. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor
24. Evolution of HIV-1 multidrug-resistant genotypes during combination therapy and after the cessation of antiretroviral drugs
25. Dramatic HIV DNA degradation associated with spontaneous HIV suppression and disease-free outcome in a young seropositive woman following her infection
26. Concentration–response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients
27. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy
28. Cellular and plasma viral load in patients infected with HIV-2
29. Evaluation of self-collected rectal swabs for the detection of bacteria responsible for sexually transmitted infections in a cohort of HIV-1-infected patients
30. Protein S Deficiency and HIV Infection
31. Porphyria cutanea tarda associated with HIV infection
32. Multidrug Resistance Genotypes (Insertions in the β3–β4 Finger Subdomain and MDR Mutations) of HIV-1 Reverse Transcriptase from Extensively Treated Patients: Incidence and Association with Other Resistance Mutations
33. Emergence of uncommon HIV-1 non-B subtypes and circulating recombinant forms and trends in transmission of antiretroviral drug resistance in patients with primary infection during the 2013-2015 period in Marseille, Southeastern France
34. First Real Life Evidence of New Direct-acting Antivirals (DAA) in Co-infected HIV HCV Patients: Better than Ever
35. Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort
36. Daclatasvir plasma concentration assessment in HIV–HCV-coinfected real-life patients
37. Multidisciplinary approach for the treatment of 1155 HCV/HCV-HIV co-infected patients
38. Feasibility and Acceptability of Anal Self-Sampling for Human Papillomavirus Screening in HIV-Infected Patients
39. Recombinant hepatitis C viruses that might hamper accurate genotype classification and choice of treatment with direct-acting agents, southeastern France
40. Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in an HIV–HCV coinfected patient
41. Antiretroviral Therapy Does Not Block the Secretion of the Human Immunodeficiency Virus Tat Protein
42. Pilot phase I study using zidovudine in association with a 10-day course of anti-CD4 monoclonal antibody in seven AIDS patients
43. TT virus infection: prevalence of elevated viraemia and arguments for the immune control of viral load
44. Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients
45. Successful Treatment with Sofosbuvir of Fibrosing Cholestatic Hepatitis C after Liver Transplantation in an HIV–HCV-Coinfected Patient
46. Correlations Between Gene Rearrangements and Immunoreactivity of Reed-Sternberg Cells in Paraffin Sections: A Genotypic and Phenotypic Study of 14 Cases of Hodgkin's Disease
47. Evaluation of self-collected rectal swabs for the detection of bacteria responsible for sexually transmitted infections in a cohort of HIV-1-infected patients.
48. Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
49. Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.